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Abstract
Background: Clostridium difficile is the major cause of pseudomembranous colitis associated with antibiotic use,
and the spread of the hypervirulent epidemic ribotype 027/NAP-1 strain across hospitals worldwide has re-focused
attention on this nosocomial pathogen. The overall incidence and trend of C. difficile-associated disease (CDAD) in
Singapore is unknown, and a surveillance program to determine these via formal laboratory-based reporting was
established.
Findings: Laboratory and pharmacy data were collated from one tertiary and two secondary hospitals on a
quarterly basis between 2006 and 2008. All hospitals tested for C. difficile using Immunocard Toxins A&B (Meridian
Bioscience Inc., Cincinnati, OH) during this period. Duplicate positive C. difficile results within a 14-day period were
removed. The CDAD results were compared with trends in hospital-based prescription of major classes of
antibiotics.
Overall CDAD incidence-density decreased from 5.16 (95%CI: 4.73 - 5.62) cases per 10,000 inpatient-days in 2006 to
2.99 (95%CI: 2.67 to 3.33) cases per 10,000 inpatient-days in 2008 (p < 0.001), while overall rates for C. difficile
testing increased significantly (p < 0.001) within the same period. These trends were mirrored at the individual
hospital level. Evaluation of antibiotic prescription data at all hospitals showed increasing use of carbapenems and
fluoroquinolones, while cephalosporin and clindamycin prescription remained stable.
Conclusions: Our results demonstrate a real decline of CDAD rates in three large local hospitals. The cause is
unclear and is not associated with improved infection control measures or reduction in antibiotic prescription. Lack
of C. difficile stool cultures as part of routine testing precluded determination of the decline of a major clone as a
potential explanation. For more accurate epidemiological trending of CDAD and early detection of epidemic
clones, data collection will have to be expanded and resources set in place for reference laboratory culture and
typing.
Background
Clostridium difficile is an anaerobic Gram-positive bacil-
lus that is the major cause of pseudomembranous colitis
associated with antibiotic use, accounting for 15%-25%
of nosocomial cases of antibiotic-associated diarrhea
[1,2]. The spread of the hypervirulent epidemic ribotype
027/NAP-1 strain across hospitals in US, Canada and
Europe amidst rising incidence and mortality of C. diffi-
cile-associated disease (CDAD) in the past decade has
r e - f o c u s e da t t e n t i o no nt his successful nosocomial
pathogen [1-4]. In response, the Society for Healthcare
Epidemiology of America (S H E A )p r o p o s e di n t e r i m
standardized definitions and recommendations for
CDAD surveillance in 2007 [5] and, together with the
Infectious Diseases Society of America, updated clinical
practice guidelines for CDAD in adults in 2010 [2].
In Singapore, the overall incidence and trend of
CDAD is unknown. Data from one 1,400-bed secondary
public hospital showed a rising incidence-density of
CDAD from 1.49 cases per 10,000 inpatient-days in
2001 to 6.64 cases per 10,000 inpatient-days in 2006
that was coupled with a similar steep jump in the num-
ber of stool specimens tested [6]. A shorter study using
a different methodology carried out over a five-month
period between 2002 and 2003 at a 1,600-bed tertiary
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5.38 cases per 10,000 inpatient-days [7].
In an effort to determine the trend and incidence of
CDAD locally, formal laboratory-based surveillance was
conducted by the Network for Antimicrobial Resistance
Surveillance (Singapore) - a voluntary group of health-
care professionals. The CDAD results were compared
with trends in hospital-based prescription of major
classes of antibiotics.
Methods
A prospective surveillance program coupling laboratory-
based surveillance of CDAD incidence and pharmacy-
based surveillance of antibiotic prescription was imple-
mented in five of six public sector hospitals in Singapore
from January 2006 to December 2008. Two hospitals
were subsequently dropped from analysis - the first
b e c a u s eo n l yr e s u l t sf o r2 0 0 8w e r ea v a i l a b l e ,w h i l et h e
second was a specialized maternal and child hospital
where CDAD rates were very low (fewer than 5 cases
per quarter on average) and reliable comparative anti-
biotic prescription data could not be obtained because
of the large pediatric population.
Hospital 1 is a 1,600-bed tertiary hospital; Hospitals 2
and 3 are secondary general hospitals with 1,400- and
900-beds respectively. C. difficile testing for specimens
obtained at Hospital 3 is performed at Hospital 1. Both
laboratories used the toxin immunoassay Immunocard
Toxins A&B (Meridian Bioscience Inc., Cincinnati, OH)
for C. difficile detection during this period. Formed
stools were routinely rejected from testing.
Anonymized C. difficile testing data (including results,
dates of testing and encoded patient identification num-
bers) and antibiotic prescription data were extracted
from each hospital’s laboratory and pharmacy electronic
information systems on a quarterly basis. Denominator
data in the form of hospital inpatient-days (the sum of
each daily inpatient census every quarter) as well as the
average length of hospitalization (LOS) for each year of
the study were obtained from the hospitals’ administra-
tive records. All data were collated and analysed cen-
trally by investigators.
Duplicate positive C. difficile results within a 14-day
period were removed. Cumulative CDAD cases - defined
as non-duplicate positive C. difficile stool testing [5] -
and C. difficile testing results from all hospitalized
patients were expressed as incidence-density per 10,000
inpatient-days respectively for every quarter. Antibiotics
were classed as carbapenems (imipenem, meropenem
and ertapenem), cephalosporins (3rd and 4th generation
cephalosporins only), fluoroquinolones (ciprofloxacin,
levofloxacin, moxifloxacin) and clindamycin. Defined
daily dose (DDD) per 100-inpatient days for each drug
prescribed every quarter was calculated following the
World Health Organization (WHO) Anatomical Thera-
peutic Chemical (ATC) classification system 2010 [8].
Statistical analysis was performed using Stata 10.1.
CDAD and C. difficile testing incidence-densities, and
each antibiotic prescription series was tested indepen-
dently for trend over time by regression analysis, cor-
rected for autocorrelation using the Cochrane-Orcutt
estimation following determination of the Durbin-Wat-
son statistic. A coefficient of determination (R
2) of > 0.3
coupled with p ≤ 0.05 was considered to be a statisti-
cally significant trend result. Confidence intervals for
individual incidence-densities were generated using the
Poisson method.
Results
Overall CDAD incidence-density decreased from 5.16
(95%CI: 4.73 - 5.62) cases per 10,000 inpatient-days in
2006 to 2.99 (95%CI: 2.67 to 3.33) cases per 10,000 inpa-
tient-days in 2008 (Coefficient = -0.28; 95%CI:-0.36 to
-0.20; R
2 = 0.87; p < 0.001), while overall rates for C. diffi-
cile testing increased from 45.27 (95%CI: 43.98 to 46.58)
to 68.04 (95%CI: 66.50 to 69.61) tests per 10,000 inpati-
ent-days within the same period (Coefficient = 2.95; 95%
CI:2.54 to 3.35; R
2 =0 . 9 7 ;p < 0.001). Quarterly results
highlight the gradual changes over time (Figure 1). These
trends are generally mirrored at the individual hospital
level (Additional file 1), although Hospital 3 had mark-
edly lower CDAD rates compared to the other two hospi-
tals, while Hospital 2 had the highest CDAD and
C. difficile testing rates.
Evaluation of antibiotic prescription data at all hospi-
tals showed increasing use of carbapenems and fluoro-
quinolones, while cephalosporin and clindamycin
prescription remained stable over the three-year period
(Additional file 1). In terms of DDD/100 inpatient-days,
Hospital 1 prescribed the largest relative amount of
cephalosporins while Hospital 3 prescribed the largest
amount of fluoroquinolones. There was a steep increase
in carbapenem usage in Hospital 2, from a DDD of
2.76/100 inpatient-days in 2006 to 4.88/100 inpatient-
days in 2008.
There was no significant decrease in the average LOS
(range: 5.2 to 6.1 days, p = 0.59) over the study period
at all hospitals.
Discussion
This is the first cross-institutional surveillance on
CDAD in Singapore. Our results showed a sustained
decline in the incidence-density of CDAD over three
years that was most marked in the two larger hospitals.
This is a stark reversal from the work of Lim and collea-
gues, who had shown rising rates of CDAD at their
institution (Hospital 2 in our study) in the few years
immediately preceding the start of our surveillance
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2 had dropped by more than 50% back down to pre-
2004 levels.
The cause of this decline is not obvious. During this
same period, the prescription of key classes of antibio-
tics associated with CDAD did not decrease correspond-
ingly, and the laboratory methods for C. difficile
detection did not change. The rate of C. difficile testing
has also increased significantly over time. While this
may reflect a rising incidence of nosocomial diarrhea, it
is plausible that this is the effect of increasing clinician
awareness of CDAD. A general improvement of infec-
tion control and hospital hygiene could possibly have
accounted for this trend, but there was no similar
decline in the incidence-density of methicillin-resistant
Staphylococcus aureus - a nosocomial pathogen whose
spread is correspondingly sensitive to improved infec-
tion control standards - infections during this period
using similar methodology (data not shown). There was
no significant change in the average LOS over the study
period at all hospitals, connoting no significant change
in the mean duration of exposure for each hospitalised
patient to C. difficile.
Koh et al showed that 65.6% of their institution’s
(Hospital 1 in our study) isolates in 2002-2003 belonged
to just 3 non-027 ribotypes [6]. The decline of any of
these major ribotypes - assuming these were the major
C. difficile strains circulating in local hospitals - might
account for the phenomenon presented. Unfortunately,
this remains purely speculation, as culture-based techni-
ques for C. difficile detection have not been in routine
use in our hospitals since the start of 2006.
There are several limitations in our surveillance pro-
gram. The use of a laboratory-based approach, while
acceptable according to SHEA guidelines [5], may result
in an overestimation of CDAD cases. The lack of cross-
checking of individual hospital results by a reference
laboratory may also have an impact on the accuracy of
the CDAD rates reported. These are evident when com-
pared to the 2006 results for Hospital 2, where our
laboratory CDAD rates were higher (7.50 vs. 6.64 per
10,000 inpatient-days) compared to the clinical study
performed by Lim and coworkers [6]. These issues are
further complicated by the fact that our laboratories use
commercial toxin immunoassay kits solely, which may
result in unreliable epidemiological data as C. difficile
rates continue to fall and the positive predictive value of
these tests drop correspondingly [9]. Lack of stool cul-
tures and reference laboratory testing may result in an
unacceptable delay in recognizing epidemic clones such
Figure 1 Quarterly overall incidence-density of CDAD and C. difficile testing in three Singapore hospitals.
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local hospitals. The data that is currently collated does
not allow for the differentiation of community- and
healthcare-acquired CDAD, nor does it enable tracking
of mortality associated with CDAD.
Conclusions
In conclusion, the results of our surveillance program
demonstrate a real decline of CDAD rates in three large
Singapore public hospitals. More work is required to
elucidate the cause of this reduction, perhaps via culture
and ribotyping of a sample of current C. difficile clinical
isolates and comparing these with past results. In order
to ensure more accurate epidemiological trending of
CDAD and early detection of epidemic clones, data col-
lection will have to be expanded and resources set in
place for reference laboratory culture and typing of C.
difficile.
Additional material
Additional file 1: Table S1 - Incidence-density of CDAD and C.
difficile testing at the individual hospital level, and overall antibiotic
use by class.
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